Celcuity appoints Dr. Polly Murphy to Board; reduces warrant shares to 70K

Celcuity Inc.

Warrant amended: shares reduced from 138,000 to 70,000; exercise period extended to Sept 19, 2025.
Board expanded to 7 directors; Dr. Polly Murphy elected as independent director, effective immediately.
Dr. Murphy brings 20+ years of pharma biz dev experience including 12 years at Pfizer; currently CBO of UroGen Pharma.
Dr. Murphy granted options: 16,300 shares vesting by 2023 annual meeting or April 30, 2023; plus 10,000 shares vesting over 4 years.
Company expects to dose first patient in Phase 3 gedatolisib study for HR+/HER2- breast cancer in next few months.

item 1.01 item 3.03 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Polly Murphy

Director

CELC · Celcuity Inc.

Effective: 2022-09-12
Filed: September 14, 2022, 7:59 PM ET

On September 12, 2022, the Board of Directors (the “Board”) of the Company, voted to increase the size of the Board from six members to seven members and to elect Polly Murphy, D.V.M., Ph.D. as a new director to fill the resulting vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Polly Murphy was elected as Director at Celcuity Inc..

Action: elected
Role: Director

Exact text from the filing

On September 12, 2022, the Board of Directors (the “Board”) of the Company, voted to increase the size of the Board from six members to seven members and to elect Polly Murphy, D.V.M., Ph.D. as a new director to fill the resulting vacancy.

View on SEC.gov

Celcuity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-025891

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.